Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal beast cancer: Retrospective immunohistochemical study

Croatian Medical Journal

Volumn 47, Issue 1, 2006, Pages 32-41

  Bandić, Daniela ^a   Juretić, Antonio ^b   Šarčević, Božena ^a   Śeparović, Viktor ^a   Tiljak, Mirjana Kujundžić ^c   Hudolin, Tvrtko ^b   Spagnoli, Giulio C ^d   Čović, Dinko ^a   Šamija, Mirko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MAGE A4 PROTEIN; METHOTREXATE; NY ESO 1 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644646923     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chang JC, Hilsenbeck SG. Prognostic and predictive markers. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 3rd ed. Philadelphia (PA): Lippincott, Williams and Wilkins; 2004. p. 675-96.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2005;16:1569-83.
3. Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer. 2005;6:61-76.
4. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer. 2003;97 suppl 3:825-33.
5. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606-16.
6. Roukos DH, Pavlidis N, Agnantis NJ. Gene-expression profile: the future in the outcome prediction and treatment of breast cancer. Gastric Breast Cancer. 2003;2:5-8.
7. Ross JS, Linette GP, StecJ, Clark E, Ayers M, Leschly N, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn. 2003;3:573-85.
8. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109-18.
9. Van de Vijver MJ. Microarray analysis of human breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 3rd ed. Philadelphia (PA): Lipponcott Williams and Wilkins; 2004. p. 433-9.
10. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005;23:1631-5.
11. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-75.
12. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1-15.
13. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-25.
14. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg. 2002;236:785-93.
15. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, et al. Prognostic relevance of Mage-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer. 2002;100:702-5.
16. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004;3:379-98.
17. Rampaul RS, Pinder SE, Elston CW, Ellis IO. Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol. 2001;27:229-38.
18. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic hystopathology of the breast. Edinburgh: Churchill Livingston; 1987. p. 300-11.
19. National Cancer Institute. Breast cancer. CancerNet, PDQ - Treatment -Health Professionals, date last modified 18/08/2005. Available at: http://www.nci.nih.gov/ cancer_ info/pdq/treatment/breast/health_professional/. Accessed: August 9, 2005.
20. Brdar B, Graf D, Padovan R, Nola P, Rudan N, Petrinec Z, et al. Estrogen and progesterone receptors as prognostic factors in breast cancer. Tumori. 1988;74:45-52.
21. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer. 1980;16:1513-5.
22. Juretic A, Zivkovic M, Samija M, Bagovic D, Purisic A, Viculin T, et al. Radiotherapy of stage IEA primary breast lymphoma: case report. Croat Med J. 2002;43:569-72.
23. Jardines L, Haffy BG, Doroshow JH. Stage II breast cancer. In: Pazdur R, et al, editors. Cancer management: a multidisciplinary approach. 8th ed. Melville (NY): PRR; 2004. p. 205-14.
24. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995;55:2236-9.
25. Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer. 2000;83:204-8.
26. Van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94:1156-64.
27. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer. 2000;86:835-41.
28. Kavalar R, Sarcevic B, Spagnoli G, Separovic V, Samija M, Terraciano L, et al. Expression of MAGE tumor associated antigens is inversely correlated with tumor differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch. 2001;439:127-31.
29. Sarcevic B, Spagnoli GC, Terraciano L, Schultz-Thater E, Heberer M, Gamulin M, et al. Expression of cancer/testis tumor associated antigens in invasive squamous cell cervical carcinoma. Oncology. 2003;64:443-9.
30. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/ testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 2003;4:104-9.
31. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-7.
32. Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B, Chomez P, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer. 1992;52:839-41.
33. Wascher RA, Bostick PJ, Huynh KT, Turner R, Qi K, Giuliano AE, et al. Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes. BrJ Cancer. 2001;85:1340-6.
34. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85:713-20.
35. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res. 2001;61:6682-7.